[A19-91] Pomalidomide (multiple myeloma) - Addendum to Commission A19-50
Last updated 05.12.2019
Project no.:
A19-91
Commission:
Commission awarded on 29.10.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication/Intervention:
Adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide
Result of dossier assessment:
Conclusion of dossier assessment A19-50 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information
Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.
| Project no. | Title | Status |
|---|---|---|
| A19-50 | Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-12-05 A G-BA decision was published.